Myelofibrosis | Meet The Professor: Optimizing the Management of Myelofibrosis — Part 1 of a 2-Part Series

Featuring perspectives from Dr Stephen T Oh, including the following topics: Introduction: ASH 2023 Update (0:00)  Case: A woman in her early 70s with symptomatic primary myelofibrosis (MF) receives ruxolitinib — Rao Mushtaq, MD (15:41) Case: A woman in her late 60s, a Jehovah’s Witness with multiple comorbidities, presents with splenomegaly and anemia and is diagnosed with primary MF — Bhavana (Tina) Bhatnagar, DO (27:16) Case: A woman in her mid 70s who received pacritinib for 4 years on trial now experiences disease progression with massive splenomegaly and thrombocytopenia (20K-30K) — Neil Morganstein, MD (31:50) Case: A woman in her late 50s with symptomatic primary MF has normal cytogenetics and JAK2 and DNMT3A mutations — Jeanne Palmer, MD (35:45) Case (continued): A woman in her late 50s has progressive MF after ruxolitinib and fedratinib; repeat next-generation sequencing shows JAK2, DNMT3A, IDH2 and TET2 mutations — Dr Palmer (41:09) Case: A woman in her late 60s with primary MF who discontinued ruxolitinib due to onset of congestive heart failure now has possible acute myeloid leukemia transformation — Dr Bhatnagar (50:38) Case: A woman in her late 60s with well controlled MF who has received 10 mg of ruxolitinib twice a day for 3 years develops increasing anemia and splenomegaly — Dr Palmer (52:38) CME information and select publications